FERROUS ASPARTATE

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C4H5NO4.Fe
Molecular Weight	186.932
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Fe++].N[C@@H](CC([O-])=O)C([O-])=O

InChI

InChIKey=KKPUODLFBBWJPH-DKWTVANSSA-L

InChI=1S/C4H7NO4.Fe/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+2/p-2/t2-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	Fe
Molecular Weight	55.845
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H5NO4
Molecular Weight	131.0868
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttps://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Anemia 70 Sources: http://www.medicatione.com/?c=ing&s=ferrous%20aspartate	Palliative	Not Provided 511	Unknown Approved Use Unknown
Unknown 2596
Hypochromic anemia 37 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16694502	Palliative	Not Provided 511	Unknown Approved Use Unknown
Unknown 2596
Unknown 2596
Unknown 2596
Iron deficiency 41 Sources: http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en	Primary	Approved 8583	Ferro Sanol Duodenal Approved Use Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021626lbl.pdf	Curative	Approved 8583	RADIOGARDASE Approved Use Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date 2003
Unknown 2596

PubMed

Title	Date	PubMed
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.	1932 Nov 11	17744342
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.	1937 Jul	16694502
Clinical appraisal of drugs with special reference to a new chelate hematinic.	1957 Jul 11	13452048
[FERROUS ASPARTATE IN THERAPY].	1964 Jan 1	14116934
[Historical notes on the therapy of depression].	1986 Nov 22	3541174
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.	1997 Oct	9408841
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.	2007	17426393
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.	2009	19421372
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.	2009 Nov 15	19586718
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.	2010 Dec	20039148
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.	2011 Jun 10	21439359
Tolerability of different oral iron supplements: a systematic review.	2013 Apr	23252877
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.	2013 Jul	23660146
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.	2014	25402762
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.	2017 May 1	28249212

Patents

Sample Use Guides

In Vivo Use Guide

Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:34:48 GMT 2025` Edited by `admin` on `Mon Mar 31 20:34:48 GMT 2025`
Record UNII	Z56D82TX8V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GIVOBIO AFEDL

Preferred Name

English

FERROUS ASPARTATE

Official Name

English

ASPARTIC ACID, IRON (II) SALT

Common Name

English

Ferrous aspartate [WHO-DD]

Common Name

English

FERROUS ASPARTATE [MART.]

Common Name

English

SPARTOCINE

Brand Name

English

L-ASPARTIC ACID, IRON(2+) SALT (1:1)

Common Name

English

FERROUS ASPARTATE, (+)-

Common Name

English

Classification Tree Code System Code

WHO-ATC

B03AA09